Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
Q1 2023 total revenues of $95.3 million, compared to $35.0 million in the same period in 2022 CAPLYTA Q1 2023...
Day: May 4, 2023
BridgeBio Pharma Reports First Quarter 2023 Financial Results and Business Update
- Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) has now completed last patient last visit...
SIGA Declares Special Cash Dividend of $0.45 Per Share
NEW YORK, May 04, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced...
Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
Dosed first patient in the global Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE)Expects to complete...
Selecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
- Company to implement capital prioritization initiative, extending cash runway to 2H-2025 - - $127.5 million in cash, cash equivalents, restricted...
VitalHub Announces Q1 2023 Conference Call Date
TORONTO, May 04, 2023 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) (OTCQX:VHIBF) is pleased to announce...
Avicanna and Northern Green Canada Execute Master Service Agreement to Operationalize MyMedi.ca
Avicanna and Northern Green Canada Execute Master Service Agreement to Operationalize MyMedi.ca MyMedi.ca to provide Medical Cannabis by Shoppers patients...
Theratechnologies’ Trogarzo® (Ibalizumab-uiyk) Shortens Time to HIV Undetectability and Extends Durability of Undetectability and Viral Suppression in a Matched Treatment Comparison
First-of-its-Kind Study in HIV Compares Ibalizumab Clinical Trial Experience to Matched Real-World Non-Ibalizumab OPERA® CohortData Presented at ACTHIV™ Conference Highlight...
Arbutus Reports First Quarter 2023 Financial Results and Corporate Update
Additional AB-729 off-treatment data highlighted in an oral presentation at the Global Hepatitis Summit 2023 Dosed first subject in Phase...
Altimmune to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023
GAITHERSBURG, Md., May 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it...